# Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

> **NCT02073994** · PHASE1 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 174 (actual)

## Conditions studied

- Cholangiocarcinoma
- Chondrosarcoma
- Glioma
- Other Advanced Solid Tumors

## Interventions

- **DRUG:** AG-120

## Key facts

- **NCT ID:** NCT02073994
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-01
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073994, "Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02073994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*